Why the study?
Clinical guidelines weakly recommend antiplatelet de-escalation to reduce bleeding in ACS, but the impact of body mass on platelet function testing-guided de-escalation efficacy was unknown.
Does a platelet function testing-guided de-escalation regimen improve net clinical benefit in ACS patients after PCI, and does body mass impact this efficacy?
Does a platelet function testing-guided de-escalation regimen improve net clinical benefit in ACS patients after PCI, and does body mass impact this efficacy?
Guided DAPT de-escalation provides a significant net clinical benefit in non-overweight ACS patients post-PCI, but is only equivalent to standard prasugrel in overweight patients.
Answers are grounded in this paper and cite their sources.
Body mass modifies PFT-guided de-escalation efficacy post-ACS PCI; extends TROPICAL-ACS by identifying weight-related heterogeneity in outcomes.
AIMS: Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function testing-guided de-escalation regimen in ACS patients after percutaneous coronary intervention. METHODS AND RESULTS: Patients were randomized to prasugrel (control group) or a platelet function testing-guided regimen with clopidogrel or prasugrel defined after 1-week clopidogrel. The primary endpoint was the net clinical benefit [cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium (BARC) 2-5 bleeding] for 12 months. Overweight was defined as a body mass index >25 kg/m2.Patients without overweight showed a significant net clinical benefit from the de-escalation strategy, while in overweight cases de-escalation was comparable to prasugrel treatment [hazard ratio (HR): 0.52; 95% confidence interval (CI): 0.31-0.88; P = 0.013 and HR: 0.95; 95% CI: 0.69-1.31, P = 0.717, P-non-inferiority = 0.03, respectively, P-interaction = 0.053]. The benefit of de-escalation in terms of the risk of bleeding or of the ischaemic events did not reach statistical significance. Bleeding events with de-escalation were less frequent in non-overweight patients but comparable in overweight patients (HR: 0.55; 95% CI: 0.30-1.03; P = 0.057 and HR: 0.95; 95% CI: 0.64-1.41, respectively, P-interaction = 0.147). Non-overweight patients had lower ischaemic event rates with de-escalation, while overweight cases had slightly less (HR: 0.47; 95% CI: 0.18-1.25; P = 0.128 and HR: 0.89; 95% CI: 0.53-1.50, respectively, P-interaction = 0.261). CONCLUSION: The strategy of guided dual antiplatelet therapy de-escalation was associated with a significant net clinical benefit in non-overweight patients, while the two strategies were equivalent in overweight patients.
No takes yet. Share an insight, caveat, or question.
Komócsi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: